Clinical trials: Raynaud Phenomena
Raynaud's Phenomenon, Systemic Sclerosis
The Effect of Physical Therapy on Raynaud's Phenomenon Secondary to Systemic Sclerosis
The effect of deep oscillation and biofeedback on Raynaud's phenomenon secondary to systemic sclerosis (SSc) remains to be determined.
- Trial name
- NCT00946738
- Testing
- Biofeedback, Deep oscillation
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- Charite University, Berlin, Germany
Raynaud Phenomenon
Follow-up of SPTS in Patients With Raynaud's Phenomenon
Background: Raynaud's phenomenon is a vasospasm of the extremities, leading to extensive discomfort in daily life and potentially severe ischemia. Some patients are resistant to conventional vasodilatory drug treatment.
- Trial name
- NCT04015193
- Testing
- Single-port thoracoscopic sympathicotomy (patient care)
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- University Medical Center Groningen
Raynaud's Phenomenon Secondary to Systemic Sclerosis
A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks
Systemic sclerosis (SSc) is a rare autoimmune disease in which many patients experience Raynaud's phenomenon (RP) - painful episodes where commonly fingers or toes change color and become painful, numb, or tingly, usually…
- Trial name
- RE-WARM (NCT07748000)
- Testing
- LIQ861 (treprostinil) inhalation powder - Dose Titration Arm, LIQ861 (treprostinil) inhalation powder - fixed dose arm
- Volunteers
- 75 people
- Sponsor
- Liquidia Technologies, Inc.
Raynaud Disease, Raynaud Phenomenon
Phototherapy For Treatment Of Raynaud's Phenomenon
To determine if blue light therapy can improve the symptoms of Raynaud's phenomenon, and provide parameters for ultimately designing commercial treatment devices, an investigational stationary phototherapy unit was designed and…
- Conditions
- Raynaud Disease, Raynaud Phenomenon, Raynaud Syndrome
- Trial name
- NCT04898036
- Testing
- Blue Light Therapy
- Where
- United States
- Sponsor
- University of Minnesota
Cold Hypersensitivity, Vascular System Injuries
Treatment of Frostbite Sequelae With Botulinum Toxin A
Background Digital vasospasm as part of frostbite sequelae is comparable to the vasospastic disorders found in Raynaud's phenomenon which has been successfully treated with Botulinum toxin type A injections in the palm of the…
- Conditions
- Cold Hypersensitivity, Vascular System Injuries, Vibration; Disorder, Sensory Disorders
- Trial name
- NCT06460194
- Testing
- Botuinum toxin
- Where
- Norway
- Volunteers
- healthy volunteers welcome
- Sponsor
- University Hospital of North Norway
Raynaud Disease, Hyperemia
PORH and Response to Cold in Raynaud's Phenomenon.
The main objective of the study is to determine if implication of epoxy-eicosatriénoïc acids (EETs) and NO during cutaneous post-occlusive hyperemia differs between patients with Raynaud phenomena and healthy volunteers, by…
- Conditions
- Raynaud Disease, Hyperemia, Cold
- Trial name
- REFRAIN (NCT02183779)
- Testing
- post-occlusive hyperemia, cooling box, L-NMMA and Fluconazole dermic injection
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Raynaud Phenomenon Secondary to Systemic Sclerosis
Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic Sclerosis
This study aims to assess whether or not a single injection schedule of botulinum toxin A (BTX-A) in both hands improves Raynaud phenomenon (RP) secondary to systemic sclerosis (SSc) better than a placebo at 4, 12 and 24 weeks…
- Trial name
- BRASS (NCT03717961)
- Testing
- BOTOX® solution
- Where
- France
- Volunteers
- 91 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Systemic Sclerosis, Raynaud Phenomena
The Effect of High Dose Methylprednisolone on Nailfold in Early Systemic Sclerosis ( SSc )
This is a 12 week double-blind randomized placebo controlled trial in which 30 patients with very early SSc, fulfilling the Very Early Diagnosis Of Systemic Sclerosis (VEDOSS) criteria (9) will be randomized in a 2:1 fashion to…
- Trial name
- NCT03059979
- Testing
- Methylprednisolone, sodium chloride
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Radboud University Medical Center
Secondary Raynaud's Phenomenon
Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's Phenomenon
The purpose of this study is to determine whether pl-vegf165 (Neovasculgen) is effective in the treatment of digital ulcers related to secondary Raynaud's phenomenon associated with systemic scleroderma
- Trial name
- NCT02356809
- Testing
- Neovasculgen
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Artgen Biotech
Raynaud Phenomenon
Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon
The prevalence of Raynaud phenomenon (RP), a reversible vaso-constriction with skin discoloration, is 5-10% in general population.
- Trial name
- NCT01280266
- Testing
- Udenafil or Amlodipine
- Where
- South Korea
- Volunteers
- 29 people
- Sponsor
- Seoul National University Hospital
Raynaud's Phenomenon
Dose Response to Topical Glyceryl Trinitrate in Patients With Raynaud's Phenomenon
The purpose of this study is to evaluate the blood flow response to topical Glyceryl Trinitrate when applied to the skin of patient's fingers with Raynaud's Phenomenon.
- Trial name
- NCT00700518
- Testing
- Glyceryl Trinitrate
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Procris Pharmaceuticals
Raynaud Phenomenon Due to Trauma, Raynaud Disease
Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud
Objective: To compare the efficacy of topical 10% nifedipine versus 5% sildenafil in patients with secondary Raynaud's phenomenon (RP).
- Conditions
- Raynaud Phenomenon Due to Trauma, Raynaud Disease, System; Sclerosis, Lupus Erythematosus, Systemic
- Trial name
- NCT03027674
- Testing
- 10% nifedipine cream, 5% sildenafil cream
- Where
- Chile
- Volunteers
- 10 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Raynaud Disease, Raynaud Phenomenon
Investigation of the Rewarming og the Fingers After Cooling and the Autonomic Nervous System in Raynaud's Phenomenon
Patients with Raynaud's disease have an increased tendency of chest pain and migraine, and studies indicate that the disease might be associated with increased cardiovascular morbidity and mortality.
- Conditions
- Raynaud Disease, Raynaud Phenomenon, Hand and Arm Vibration Syndrome, Diabetes Mellitus
- Trial name
- RaynAUT (NCT03094910)
- Testing
- Examination of vibration perception threshold in fingertips, Ewing's tests, Tilt table test
- Where
- Denmark
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- Herlev Hospital
Raynaud's Phenomenon Secondary to Systemic Sclerosis
A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis
The purpose of this study is to determine whether oral temanogrel improves digital blood flow in participants with Raynaud's phenomenon secondary to systemic sclerosis (SSc-RP) as a potential safe and effective treatment for…
- Trial name
- NCT04915950
- Testing
- Temanogrel
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 13 people
- Sponsor
- Pfizer
Scleroderma, Systemic, Scleroderma, Diffuse
Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis
Early phases of systemic sclerosis is characterized by inflammatory and microvasculature alterations. Sildenafil citrate has been shown to have vasodilatory effects and to enhance vasculogenesis.
- Conditions
- Scleroderma, Systemic, Scleroderma, Diffuse, Scleroderma, Limited, Raynaud Phenomenon
- Trial name
- NCT01347008
- Testing
- Sildenafil citrate
- Where
- Brazil
- Volunteers
- 41 people
- Sponsor
- Federal University of São Paulo
Raynaud's Phenomenon, Skin Necrosis
Prognostic Influence of Light Rheography Measurement of Patients With Secondary Raynaud Syndrome With Ulcers on Hands
The purpose of this study is to evaluate the prognostic influence of light rheography measurement at the fingertips from subjects with secundary Raynaud syndrome.
- Trial name
- Anti-Vasospasm (NCT01378845)
- Testing
- Tracleer, Prostavasin
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Christoph Hehrlein
Raynaud Phenomenon, Raynaud Disease
Effectiveness of Electric Stimulation Therapy in Raynaud's Phenomenon
The purpose of this study is to analyze the effects of an intervention with galvanic electrical current on the number of attacks , temperature, pain, peripheral blow flow and upper limb functionality in patients with Raynaud's…
- Trial name
- NCT03699436
- Testing
- Electrotherapy with Galvanic Current, Control without Electric Stimulation Therapy
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Universidad de Granada
Raynaud's Disease
Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon
The purpose of this clinical study is to determine the response to two different dosage strengths of a topical nitroglycerin gel in patients with Raynaud's Phenomenon.
- Trial name
- NCT00480753
- Testing
- Nitroglycerin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- MediQuest Therapeutics
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis
The purpose of this study is to evaluate pharmacodynamics (PD) in adult subjects with a diagnosis of Raynaud's Phenomenon secondary to Systemic Sclerosis (SSc).
- Trial name
- NCT02228850
- Testing
- Alprostadil
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
Systemic Sclerosis, Raynaud Phenomenon
Early Diagnosis of SSc in the General Rheumatology Clinic - Pilot
The goal of this observational pilot data acquisition study is to establish if target users can obtain diagnostic quality images in the clinic, from participants with Systemic Sclerosis (SSc), and SSc spectrum conditions.
- Trial name
- NCT06291142
- Testing
- Observation - Nailfold capillaroscopy
- Where
- United Kingdom
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- University of Manchester